<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The present study was to investigate the effects and mechanism of <z:chebi fb="0" ids="15864">Luteolin</z:chebi> on myocardial <z:mpath ids='MPATH_124'>infarct</z:mpath> size, cardiac function and cardiomyocyte <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in diabetic rats with <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>/reperfusion (I/R) injury </plain></SENT>
<SENT sid="1" pm="."><plain>METHODOLOGY/PRINCIPAL FINDINGS: Diabetic rats underwent 30 minutes of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> followed by 3 h of reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>Animals were pretreated with or without <z:chebi fb="0" ids="15864">Luteolin</z:chebi> before coronary artery ligation </plain></SENT>
<SENT sid="3" pm="."><plain>The severity of myocardial I/R induced LDH release, <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, <z:mpath ids='MPATH_124'>infarct</z:mpath> size, cardiac function impairment, cardiomyocyte <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were compared </plain></SENT>
<SENT sid="4" pm="."><plain>Western blot analysis was performed to elucidate the target proteins of <z:chebi fb="0" ids="15864">Luteolin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The inflammatory cytokine production were also examined in ischemic myocardium underwent I/R injury </plain></SENT>
<SENT sid="6" pm="."><plain>Our results revealed that <z:chebi fb="0" ids="15864">Luteolin</z:chebi> administration significantly reduced LDH release, decreased the incidence of <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, attenuated myocardial <z:mpath ids='MPATH_124'>infarct</z:mpath> size, enhanced left ventricular ejection fraction and decreased myocardial apoptotic <z:hpo ids='HP_0011420'>death</z:hpo> compared with I/R group </plain></SENT>
<SENT sid="7" pm="."><plain>Western blot analysis showed that <z:chebi fb="0" ids="15864">Luteolin</z:chebi> treatment up-regulated anti-apoptotic proteins FGFR2 and LIF expression, increased BAD phosphorylation while decreased the ratio of Bax to Bcl-2 </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="15864">Luteolin</z:chebi> treatment also inhibited MPO expression and inflammatory cytokine production including IL-6, IL-1a and TNF-a </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, co-administration of <z:chebi fb="0" ids="52289">wortmannin</z:chebi> and <z:chebi fb="0" ids="15864">Luteolin</z:chebi> abolished the beneficial effects of <z:chebi fb="0" ids="15864">Luteolin</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/SIGNIFICANCE: This study indicates that <z:chebi fb="0" ids="15864">Luteolin</z:chebi> preserves cardiac function, reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> size and cardiomyocyte apoptotic rate after I/R injury in diabetic rats </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="15864">Luteolin</z:chebi> exerts its action by up-regulating of anti-apoptotic proteins FGFR2 and LIF expression, activating PI3K/Akt pathway while increasing BAD phosphorylation and decreasing ratio of Bax to Bcl-2 </plain></SENT>
</text></document>